Table 6– Results of the clinical evaluation
ScoreTotal
LowIntermediateHigh
Subjects n2254673
Sensitisation
 Wheat allergens IgE ≥0.7 kU·L−11 (50.0)9 (36.0)19 (41.3)29 (39.7)
 α-Amylase allergens IgE ≥0.7 kU·L−10 (0.0)0 (0.0)7 (15.2)7 (9.6)
 Rye allergens IgE ≥0.7 kU·L−1#0/1 (0.0)2/3 (67.0)6/10 (60.0)8/14 (57.1)
 Soya allergens IgE ≥0.7 kU·L−10 (0.0)2 (8.0)1 (2.2)3 (4.1)
 Phadiatop IgE ≥0.35 kU·L−12 (100.0)8 (32.0)24 (52.2)34 (46.6)
Nonspecific bronchial hyperresponsiveness
PD20 to histamine ≤2.5 mg0/2 (0.0)8/25 (32.0)20/42 (47.6)28/69 (40.6)
Clinical diagnoses
 No clinical disease0 (0.0)5 (20.0)3 (6.5)8 (11.0)
 COPD/hypertension/hyperventilation0 (0.0)0 (0.0)3 (6.5)3 (4.1)
 Asthma (general and work-related)0 (0.0)5 (20.0)20 (43.5)25 (34.3)
 Occupational asthma0 (0.0)2 (8.0)8 (17.4)10 (13.7)
 Work-exacerbated asthma0 (0.0)0 (0.0)3 (6.5)3 (4.1)
 Rhinitis, rhinoconjunctivitis1 (50.0)16 (64.0)34 (73.9)51 (69.9)
 Work-related allergic rhinitis or rhinoconjunctivitis1 (50.0)9 (36.0)20 (43.5)30 (41.1)
  • Unless otherwise indicated, data are presented as n (%) or n/N (%), where N is the number of subjects assessed. IgE: immunoglobulin E; PD20: provocative dose of agent causing a 20% fall in forced expiratory volume in 1 s; COPD: chronic obstructive pulmonary disease. #: only assessed in workers reporting symptoms when exposed to rye (n = 14); : Phadia, Nieuwegein, the Netherlands.